同步放化疗治疗局限期小细胞肺癌的疗效

Efficacy of concurrent chemoradiotherapy for limited stage small cell lung cancer

目的探讨同步放化疗治疗局限期小细胞肺癌患者的临床疗效。方法选取2012年5月至2015年9月间福建省龙岩市第二医院收治的158例局限期小细胞肺癌患者进行回顾性分析,根据治疗方法不同分为研究组80例和对照组78例。研究组患者采用同步放化疗治疗,对照组患者采用序贯放化疗治疗,比较两组患者的近期临床疗效、不良反应和近期生存率。结果研究组患者治疗总有效率为71. 3%,高于对照组的47. 4%,差异有统计学意义(P <0. 05)。两组患者治疗期间均出现了放射性食管炎、骨髓抑制、恶心呕吐、白细胞下降与血小板下降等不良反应,但两组比较,差异均无统计学意义(均P> 0. 05)。研究组患者1年、2年和3年的生存率为87. 5%、72. 5%和51. 3%,均高于对照组的70. 5%、51. 3%和29. 5%,差异均有统计学意义(均P <0. 05)。结论局限期小细胞肺癌患者采用同步放化疗治疗较序贯治疗的近期临床疗效更为理想,有效延长了患者生存时间,适于临床应用。

Objective To explore the clinical efficacy of concurrent chemoradiotherapy for limited stage small cell lung cancer. Methods The clinical data of 158 patients with limited stage small cell lung cancer treated at The Second Hospital of Longyan from May 2012 to September 2015 were retrospectively analyzed. The patients were divided into a study group( 80 patients) and a control group( 78 patients) according to the treatment strategy. The study group received concurrent chemoradiotherapy and the control group received sequential chemoradiotherapy. The short-term clinical efficacy,adverse reactions and shortterm survival were compared between the two groups. Results The overall efficacy rate of the study group was 71. 3%,which was higher than 47. 4% of the control group( P < 0. 05). Adverse reactions including radioactive esophagitis,myelosuppression,nausea and vomiting,leukopenia,and thrombocytopenia occurred in both groups but there was no statistically significant difference between them( all P > 0. 05). The1-,2-,and 3-year survival rates of the study group were 87. 5%,72. 5%,and 51. 3%,which were higher than 70. 5%,51. 3%,and 29. 5% of the control group( all P < 0. 05). Conclusion Compared with sequential therapy,concurrent chemoradiotherapy for limited-stage small cell lung cancer has a better shortterm clinical efficacy and prolongs the survival time.